JBIO JBIO JADE201 — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by JBIO in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about JBIO's jade201 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is JBIO's JADE201 — research and development expense?
- JBIO (JBIO) reported JADE201 — research and development expense of $2.88M in Q1 2026.
- How has JBIO's JADE201 — research and development expense changed year-over-year?
- JBIO's JADE201 — research and development expense decreased by 44.2% year-over-year, from $5.15M to $2.88M.
- What does JADE201 — research and development expense mean?
- This metric represents the total costs incurred by the JADE201 business segment for research and development activities, including preclinical studies, drug discovery, and clinical trial preparation. It reflects the company's investment in advancing its specific therapeutic pipeline and pipeline-enabling technologies. Monitoring this expenditure helps investors assess the pace of innovation and the capital intensity required to bring the segment's drug candidates toward regulatory approval.